Predicting Response to PRRT: Development and Validation of a Blood-Based Predictive Biomarker

#2216

Introduction: We have developed a blood-based tool (gene expression analysis and tumor grade) for predicting PRRT efficacy.

Aim(s): Validate the clinical utility of the biomarker in two independent prospective cohorts and in two independent non-PRRT cohorts.

Materials and methods: Three 177Lu-PRRT treatment cohorts (n=158 [IRST Meldola; EMC-Rotterdam; ZKK-Bad Berka]) and 2 Comparator cohorts (GEPNETs (n=106, in a watch-and-wait program) and SSA-treated GEP-NETs (n=28). Baseline evaluations: Grade (Ki67) and NETest (qRT-PCR). A logistic regression model (PPQ) including genes regulating metabolism/growth factor signaling and grade. Two prediction outputs: Predicted Responder vs Predicted Non-Responder. Response was by RECIST 1.1 criteria [Responder (stable, partial and complete response) vs Non-Responder (disease progression)]. Statistics: Kaplan-Meier survival analysis.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Bodei L

Authors: Bodei L, Kidd M, van der Zwan W, Singh A, Severi S,

Keywords: Biomarker, carcinoid, PRRT, prediction, therapy, efficacy, stratification,